Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308))
Journal
Annals of Oncology
Journal Volume
29
Journal Issue
10
Date Issued
2018
Author(s)
Curigliano G.
Burstein H.J.
Winer E.P.
Gnant M.
Dubsky P.
Loibl S.
Colleoni M.
Regan M.M.
Piccart-Gebhart M.
Senn H.-J.
Th?rlimann B.
Andr? F.
Baselga J.
Bergh J.
Bonnefoi H.
Brucker S.Y.
Cardoso F.
Carey L.
Ciruelos E.
Cuzick J.
Denkert C.
Di Leo A.
Ejlertsen B.
Francis P.
Galimberti V.
Garber J.
Gulluoglu B.
Goodwin P.
Harbeck N.
Hayes D.F.
Huober J.
Khaled H.
Jassem J.
Jiang Z.
Karlsson P.
Morrow M.
Orecchia R.
Osborne K.C.
Pagani O.
Partridge A.H.
Pritchard K.
Ro J.
Rutgers E.J.T.
Sedlmayer F.
Semiglazov V.
Shao Z.
Smith I.
Toi M.
Tutt A.
Viale G.
Watanabe T.
Whelan T.J.
Xu B.
Abstract
Ann Oncol 2017; 28: 1700–1712 (doi: 10.1093/annonc/mdx308) In the original article, panel member H. Khaled’s first and surnames were transposed. This has now been corrected. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Annals of OncologyVol. 28Issue 8PreviewThe 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer. Treatments were assessed in light of their intensity, duration and side-effects, seeking where appropriate to escalate or de-escalate therapies based on likely benefits as predicted by tumor stage and tumor biology. The Panel favored several interventions that may reduce surgical morbidity, including acceptance of 2 mm margins for DCIS, the resection of residual cancer (but not baseline extent of cancer) in women undergoing neoadjuvant therapy, acceptance of sentinel node biopsy following neoadjuvant treatment of many patients, and the preference for neoadjuvant therapy in HER2 positive and triple-negative, stage II and III breast cancer.
SDGs
Publisher
Elsevier Ltd
Type
corrigendum